Skip to main content

Advertisement

Table 4 Anthropometric measurements (PP) at different control times (T1 baseline and, T5, T9, T13) in groups treated with PG and O

From: Randomised, double-blind, clinical investigation to compare orlistat 60 milligram and a customized polyglucosamine, two treatment methods for the management of overweight and obesity

Variable Group T1 T1 - T5 T1 - T9 T1 - T13
Weight (kg) polyglucosamine 100.9 ± 13.44 3.71 ± 2.67 5.49 ± 2.63# 6.74 ± 3.14#
orlistat 97.9 ± 11.55 2.82 ± 1.42 3.43 ± 1.69 4.78 ± 2.24
BMI (kg/m2) polyglucosamine 34.6 ± 3.69 1.26 ± 0.88 1.89 ± 0.90# 2.33 ± 1.09*
orlistat 34.7 ± 4.76 1.00 ± 0.54 1.23 ± 0.64 1.71 ± 0.86
WC (cm) polyglucosamine 113.4 ± 11.13 3.81 ± 3.11 5.96 ± 4.13 8.33 ± 4.42*
orlistat 109.5 ± 10.13 2.61 ± 2.65 5.29 ± 2.47 6.10 ± 3.43
  1. #p<0.01, * p < 0.05